The increase of FGF21 expression by CO is associated with alleviating metabolic disorders, including improving glucose tolerance and insulin sensitivity and in ameliorating hepatic steatosis and adipose tissue dysfunction. This evidence concerns the gene INS and Hepatic steatosis.